FindTrial
Sign In

Kagami/SDS Project

A Multi-centre, Single-blind, Randomized, Parallel Group, Phase 2b Dose Rate Range Finding Study to Find Maintenance Dose Rate Range of ICI35,868 for the Minimal-to-moderate Sedation on Gastrointestinal Endoscopic Tests (Including Endoscopic Polypectomy)

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221299
Enrollment
Unknown
Registered
2010-11-09
Start date
2010-11-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Endoscopic Tests (Including Endoscopic Polypectomy)

Interventions

investigational material(s) Generic name etc : Propofol Intravenous injection 1% INN of investigational material : Propofol Therapeutic category code : 111 General anesthetics Dosage and Administratio

Sponsors

AstraZeneca
Lead Sponsor
Johnson & Johnson K.K., Medical Company
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Be undergoing a non-emergent esophagogastroduodenoscopy (EGD) or colonoscopy.

Exclusion criteria

Exclusion criteria: - American Society of Anesthesiologists (ASA) grade III, IV V and VI - Baseline oxygen saturation=35

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026